Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.46 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.46 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31195582 | 1.00 | CRBN (0.54) | CRBNCSNK1A1ESR1IKZF2IKZF1 | |
| SCHEMBL25438799 | 0.96 | CRBN (0.53) | CRBNCSNK1A1ESR1IKZF2IKZF1 | |
| SCHEMBL24132355 | 0.88 | CRBN (0.55) | CRBNCSNK1A1ESR1IKZF2IKZF1 | |
| SCHEMBL28451413 | 0.86 | CRBN (0.63) | CRBNDDB1IKZF3 | |
| SCHEMBL29683772 | 0.86 | CRBN (0.63) | CRBNDDB1IKZF3 | |
| SCHEMBL25431714 | 0.85 | CRBN (0.42) | CRBNCSNK1A1ESR1GSPT1DDB1 | |
| SCHEMBL20120459 | 0.84 | CRBN (0.63) | CRBNCSNK1A1ESR1IKZF2IKZF1 | |
| SCHEMBL25266460 | 0.84 | CRBN (0.47) | CRBNCSNK1A1ESR1IKZF2IKZF1 | |
| SCHEMBL24132346 | 0.83 | CRBN (0.58) | CRBNCSNK1A1IKZF2IKZF1GSPT1 | |
| SCHEMBL25429101 | 0.82 | CRBN (0.60) | CRBNCSNK1A1ESR1IKZF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000676-A1 | CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2023186069-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
| EP-3947376-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | Astrazeneca AB (SE) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020201080-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA AB (SE) | 2020-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | CRBN 576/4885CSNK1A1 548/4885ESR1 1/4885 |
| US-20260000676-A1 | CHROMAN DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, ESRRB | CRBN 347/4885CSNK1A1 463/4885ESR1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.